TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes

BACKGROUND: TLR9 agonists are being developed as immunotherapy against malignancies and infections. TLR9 is primarily expressed in B cells and plasmacytoid dendritic cells (pDCs). TLR9 signalling may be critically important for B cell activity in lymph nodes but little is known about the in vivo imp...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:EBioMedicine
Main Authors: Schleimann, Mariane H., Kobberø, Maria-Louise, Vibholm, Line K., Kjær, Kathrine, Giron, Leila B., Busman-Sahay, Kathleen, Chan, Chi Ngai, Nekorchuk, Michael, Schmidt, Manuel, Wittig, Burghardt, Damsgaard, Tine E., Ahlburg, Peter, Hellfritzsch, Michel B., Zuwala, Kaja, Rothemejer, Frederik H., Olesen, Rikke, Schommers, Phillipp, Klein, Florian, Dweep, Harsh, Kossenkov, Andrew, Nyengaard, Jens R., Estes, Jacob D., Abdel-Mohsen, Mohamed, Østergaard, Lars, Tolstrup, Martin, Søgaard, Ole S., Denton, Paul W.
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier 2019
Assuntos:
Research paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6642412/
https://ncbi.nlm.nih.gov/pubmed/31300344
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2019.07.005
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares